PPMI Flagship Cohort: Neuronal Alpha-Synuclein Disease Integrated Biological Staging System (NSD-ISS) & SAA Dataset
Study Design & Technical Specifications
Sample Size / Cohort
2,100+ Longitudinal Subjects
Subject / Study Model
CNS Experimental / Clinical Model
Analytical Modalities
Primary Abstract & Repository Description
Source: The Michael J. Fox FoundationEditorial Critique, Methodological Value & Reusability Guide
1. Scientific Context & Premise
Primary Premise (The Michael J. Fox Foundation): "Longitudinal Parkinson’s Progression Markers Initiative (PPMI) dataset spanning >2,000 sporadic PD, prodromal RBD/hyposmia, and LRRK2/GBA1 carriers with CSF alpha-synuclein seed amplification assay (SAA), DAT-SPECT, and 3T MRI." Within Parkinson's Disease (PD), this work examines MJFF, PPMI, Alpha-Synuclein SAA, NSD-ISS, LRRK2 in relation to α-synuclein seed amplification assays (SAA), LRRK2/GBA1 variants, DAT-SPECT, and digital motor kinematics. Authored by Simuni T, Chahine LM, Marek K.
2. Study Architecture & Findings
Study Architecture: Experimental / Clinical CNS Design (2,100+ Longitudinal Subjects) utilizing CSF Biomarkers, DAT-SPECT, Structural MRI, Whole-Genome Sequencing [DOI: 10.1016/S1474-4422(23)00405-2]. Key reported conclusion: "Longitudinal Parkinson’s Progression Markers Initiative (PPMI) dataset spanning >2,000 sporadic PD, prodromal RBD/hyposmia, and LRRK2/GBA1 carriers with CSF alpha-synuclein seed amplification assay (SAA), DAT-SPECT, and 3T MRI."
3. Secondary Analysis & Reusability
Secondary Analysis Applications: (1) Cross-referencing CSF Biomarkers, DAT-SPECT, Structural MRI, Whole-Genome Sequencing variables (MJFF, PPMI, Alpha-Synuclein SAA, NSD-ISS, LRRK2) against open repositories in Parkinson's Disease (PD); (2) Benchmarking feature distributions and effect sizes reported in "PPMI Flagship Cohort: Neuronal Alpha-Synuclein Disease Integrated Biological Sta"; (3) Informing cohort stratification and endpoint selection.
4. Methodological Caveats & Governance
Methodological Note: When integrating these CSF Biomarkers, DAT-SPECT, Structural MRI, Whole-Genome Sequencing findings, account for cohort-specific inclusion criteria (2,100+ Longitudinal Subjects), potential site/instrument batch effects, and repository license terms (PPMI Open Research Data Use Agreement).
Data Access, Reproducibility & Analysis Starter Guide
BIDS (Brain Imaging Data Structure) v1.9+
Quick Data Access & Structured Export
Open the primary repository directly or download structured metadata (JSON / CSV) in one click.
This neuroimaging resource follows the Brain Imaging Data Structure (BIDS) specification, organizing raw NIfTI volumes (.nii.gz), acquisition parameters (.json sidecars), and participant phenotype tables (participants.tsv) in a deterministic directory hierarchy.
Tags & Modalities
Related Parkinson's & Movement Research & Datasets
Explore All DatasetsOpenNeuro ds003505: Dopaminergic Striato-Cortical Circuit Connectivity in Parkinson’s Disease during Motor Execution
This open-access 3T fMRI dataset evaluates striato-cortical circuit connectivity across 72 Parkinsonian patients and controls under levodopa ON vs. OFF states. Complete with behavioral logs, it offers foundational data for modeling dopaminergic network dynamics in motor execution.
Dandiset 000026: Subthalamic Nucleus Local Field Potentials (LFP) and Beta-Band Dynamics in Parkinson’s Patients
High-density intraoperative and chronically implanted deep brain stimulation (DBS) electrode recordings during motor resting and movement states from 34 patients with idiopathic PD.
Focal drug uncaging for the precise control of endogenous nicotinic receptors in behaving mice
Nicotinic acetylcholine receptors shape diverse brain functions, including reward, aversion, and pain, but dissecting their roles in vivo requires drug delivery with spatiotemporal precision that conventional pharmacology cannot provide. Here we establish in vivo photopharmacology of endogenous nico...
Peripheral immunoinflammatory markers and clinical correlations in Parkinson's disease patients carrying LRRK2 G2385R and R1628P variants
Peripheral inflammation in Parkinsons disease (PD) remains poorly characterised among carriers of Asian-prevalent LRRK2 G2385R and R1628P variants. We investigated plasma immunoinflammatory markers (i.e., IL-6, TNF-, CCL2, CX3CL1, CCL5, and VCAM-1) via multiplex immunoassay in 240 participants: PD-G...
Continuous High-Frequency Smartwatch Sensor Telemetry Predicts Parkinson’s Motor Fluctuation Subtypes
A 24-month longitudinal cohort of 650 Parkinson’s patients monitored with wrist-worn IMU accelerometer arrays establishes automated machine learning scores correlating with MDS-UPDRS Part III subscores.
Pharmacological Inhibition of mTORC1 Reduces Neural Death and Damage Volume After MCAO by Modulating Microglial Reactivity
Preclinical evaluation of novel mTORC1 inhibitors in neurodegenerative models demonstrating reduced neuroinflammation.
Active Clinical Trials & Pipeline in Parkinson's & Movement
View Clinical PipelineFive-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease.
Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study.
Safety and Feasibility of Serial Lumbar Punctures: Long-term Results from the Parkinson's Progression Markers Initiative.
Related Data & Resources
Academic Research & Medical Information Disclaimer
This page provides structured scientific metadata, methodological critiques, and open-data reusability guidelines intended strictly for neuroscience researchers and data scientists. It does not constitute medical advice, clinical diagnosis, or treatment recommendations.
Was this resource helpful?
Help improve data curation by sharing your feedback.